Diabetes technology has been one of the busiest medical device spaces this year, with new developments from makers of both continuous glucose monitors (CGMs) and insulin pumps.
The emergence of over-the-counter CGMs has been a top story in diabetes tech and the overall medical technology industry. The Food and Drug Administration cleared the first OTC glucose sensors from both Abbott and Dexcom earlier, opening up a new market to the companies.
The devices are built with technology similar to current CGMs, but they are intended for people who do not use insulin, either people who do not have diabetes or who have Type 2 diabetes but do not take insulin.
Dexcom launched its Stelo device in the U.S. in late August, while Abbott debuted its Lingo sensor about a week after. Abbott will follow its Lingo launch with a second OTC sensor, called Libre Rio.
In another important development in diabetes tech, Insulet won FDA clearance for its Omnipod 5 insulin pump for people with Type 2 diabetes. Omnipod 5 is now the first product that provides access for people with Type 1 and people with Type 2 diabetes to an automated insulin delivery system, when an insulin pump and CGM coordinate to deliver insulin when it’s needed.
Meanwhile, Abbott announced several partnerships, including with diabetes rival Medtronic, and Roche unveiled its first CGM.
Read on for a collection of MedTech Dive’s coverage of all the recent news and developments in the diabetes tech space:
